Searchable abstracts of presentations at key conferences in endocrinology

ea0065p139 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Clinical spectrum of endocrine toxicities of Immune checkpoint therapy: single centre experience

Joshi Mamta , Duffy Leo , Velusamy Anand , Papa Sophie , Carroll Paul

Introduction: Checkpoint inhibitor (CPI) related endocrine toxicities are increasingly commonly with the use of these new cancer agents. With one of the largest cancer departments in UK, we studied the clinical management and outcome of patients who developed different endocrine toxicities over the last five years, with the use of CTLA-4, PD-1 and PDL-1 agents.Methods: All patients treated with CPI between 1 Jan 2014 to 31 Jan 2019 were included for the ...

ea0063p1041 | Interdisciplinary Endocrinology 2 | ECE2019

Identification, management and outcome of endocrine toxicities related to immune checkpoint inhibitors

Duffy Leo , Joshi Mamta , Velusamy Anand , Papa Sophie , Carroll Paul

Introduction: Immunotherapy has become standard treatment for an increasingly wide range of cancers. Checkpoint inhibitors (ICT; CTLA4, PD1 & PD-L-1) can cause endocrine toxicity, principally affecting the pituitary and thyroid glands. We have studied the clinical management and outcome of patients with endocrine adverse effects over 5 years at our cancer centre.Methods: All patients treated with ICT agents between 1 Jan 2014 to 31 Jan 2019 were incl...

ea0063p1042 | Interdisciplinary Endocrinology 2 | ECE2019

Use of Simple Referral system to provide quality care in the management of Endocrine Toxicities with Immune checkpoint therapy: Auditing the effectiveness of a new referral system

Duffy Leo , Joshi Mamta , Velusamy Anand , Papa Sophie , Carroll Paul

Introduction: Immune checkpoint therapies are novel cancer agents, which have been associated with the development of endocrine toxicities. ESMO and SfE endorsed management guidelines have been helpful for the early recognition of these toxicities, but in clinical practice, having early access to specialist endocrine advice improves the decision making and effective use of these agents when toxicities occur. In response to need we developed an easily accessible interdisciplina...

ea0070aep590 | Pituitary and Neuroendocrinology | ECE2020

High-dose corticosteroid treatment of immunotherapy-induced hypophysitis: A multi-centric, restrospective analysis

Amereller Felix , Joshi Mamta , DEUTSCHBEIN Timo , Duffy Leo , Carroll Paul , Papa Sophie , Schilbach Katharina , Schopohl Jochen , Störmann Sylvère

Introduction: Hypophysitis is a frequent side effect of oncologic immunotherapy. The recommended standard treatment is systemic high-dose corticosteroids (HDS), however, recent studies have questioned the benefits of this treatment. We sought to examine the effect of HDS on immunotherapy-induced hypophysitis (IH) in a multi-centric cohort.Methods: Medical records of 41 patients with IH treated by specialist endocrinologists at three tertiary referral cen...